ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0649

Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease?

Francesco Del Galdo1, Matthew Woods2, Mario Ehlers3 and Stefano Di Donato1, 1University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 2Lumanity, Manchester, United Kingdom, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Meeting: ACR Convergence 2023

Keywords: Diagnostic criteria, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune fibrotic disease with highly variable type and severity of organ involvement. Pathological changes in the skin, lungs, gastrointestinal tract, kidneys and heart determine clinical outcomes, with cardiopulmonary complications being the main cause of mortality, and musculokeletal changes and loss of hand function driving morbidity and disability. Early identification of the disease has been targeted in clinical trials in order to identify windows of opportunities for intervention, before organ damage becomes irreversible. Here we review how early SSc is defined in the literature and propose a paradigm shift in definition.

Methods: Structured, targeted searches were conducted by two reviewers in PubMed, Google Scholar, Google, and ClinicalTrials.gov in November 2021 and updated in March 2023. Search terms included ‘early systemic sclerosis’, ‘early systemic sclerosis criteria’, ‘patients with early systemic sclerosis’, ‘opportunities in early systemic sclerosis’, ‘early scleroderma criteria’ and ‘early systemic sclerosis definition’ to identify publications, treatment guidelines and clinical trial records.

Results: Published evidence defining early SSc included 103 publications, three clinical guidelines and 16 clinical trial records. Early SSc is commonly defined by one of four classification criteria (ARA, 1980; LeRoy and Medsger; Koening, 2008; or ACR/EULAR, 2013) (Table 1), often alongside a time from first non-Raynaud’s symptom (Table 2). However, there was no universal consensus on what this duration should be (generally ranging from 2 to 5 years). The key finding was the significant heterogeneity in definitions used across the literature (Table 2); however, there was consensus that Raynaud’s phenomenon is usually the first sign. Some publications even used their own variations of the classification criteria. The aim of each of the main definitions was to improve the early identification of patients, with studies adding additional criteria to provide further clarity and/or to aid treatment decisions to avoid early disease damage and burden.

Conclusion: There is no clear consensus on the optimal clinical classification criteria or disease onset duration that should be used to define early SSc. This is likely due to the differing rationale behind existing research. A common drive for a definition of ‘early’, aligned with ‘potentially reversible’, may be true at different times across different organs. Since the goal to treat early SSc patients is to prevent irreversible organ damage, we would suggest that early is not considered as a factor of time, but of severity of organ involvement, and would recommend a consensus statement exercise to align on an appropriate definition.

Supporting image 1

Table 1: Clinical diagnosis criteria for early SSc

Supporting image 2

Table 2: Definitions of early SSc in the literature


Disclosures: F. Del Galdo: AbbVie/Abbott, 5, arxx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, capella, 2, Chemomab, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Mitsubishi-Tanabe, 2, 5; M. Woods: None; M. Ehlers: Boehringer Ingelheim, 3; S. Di Donato: None.

To cite this abstract in AMA style:

Del Galdo F, Woods M, Ehlers M, Di Donato S. Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/early-systemic-sclerosis-definitions-time-to-rethink-early-in-ssc-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-systemic-sclerosis-definitions-time-to-rethink-early-in-ssc-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology